Navigation Links
Codexis Reports First Quarter 2011 Results

REDWOOD CITY, Calif., May 5, 2011 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS) today announced financial results for the first quarter ended March 31, 2011.  

First Quarter Financial Highlights:Revenue: For the first quarter of 2011, the company reported revenues of $31.0 million, an increase of 21% from $25.7 million in the first quarter of 2010.  Product revenue of $12.9 million increased 106% over the same time period driven by more than $5 million in sales of the boceprevir intermediate to be used in Merck's investigational Hepatitis C drug trade named Victrelis.  Collaborative R&D revenue of $2.7 million increased from $0.7 million in the first quarter of 2010, driven mainly by funded research for our carbon capture program.

Operating Expenses:  Research and development expenses in the first quarter of 2011 were $13.8 million, compared to $13.0 million for the first quarter of 2010.  The increase was primarily due to an increase in amortization related to intellectual property purchased from Maxygen, Inc. in the fourth quarter of 2010 and higher depreciation and stock compensation expenses. Selling, general and administrative expenses in the first quarter of 2011 increased to $9.0 million compared to $8.6 million over the same period of 2010, driven by higher stock compensation expense and higher compensation expense due to headcount increases.

Net Loss:  Net loss was ($3.5) million, or ($0.10) per share, based on 35.1 million weighted average common shares outstanding in the first quarter of 2011.   This compares to a net loss of ($1.4) million or ($0.50) per share during the first quarter of 2010.  

Adjusted EBITDA:  On a non-GAAP basis, Adjusted EBITDA decreased from $2.8 million in the first quarter of 2010 to $1.8 million in 2011. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation.  A reconciliation of net loss to Adjusted EBITDA is presented below.

Cash:  Cash, cash equivalents and marketable securities at March 31, 2011, increased to $82.0 million compared to $74.0 million at December 31, 2010.  The company generated $7.3 million in cash from operations in the first quarter.

OutlookCodexis' statements with regard to its outlook are based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.

For the full year 2011, Codexis forecasts revenues of $120 million or greater, which would represent growth of 12% or greater compared to 2010. Codexis expects 2011 Adjusted EBITDA will be $5 million or greater.

Recent EventsOn April 7, 2011, Codexis announced a partnership with Alcoa and CO2 Solution, Inc. for a carbon capture technology pilot test designed to turn emissions into beneficial commercial products.  The collaboration will use proprietary enzyme technologies to reduce the environmental impact of industrial byproducts.  This new pilot program will be funded by Alcoa and includes $13.5 million from the U.S. Department of Energy.

On March 8, 2011, Codexis named Jacques Beaudry-Losique VP Corporate Development & Strategy.  Mr. Beaudry-Losique joined Codexis from the U.S. Department of Energy, and is responsible for corporate strategic planning for Codexis' bioindustrials businesses and directing the company's government relations programs.

On February 17, 2011, Codexis announced that Byron Dorgan, former U.S. Senator from North Dakota, had been elected to the company's Board of Directors.  Senator Dorgan retired from the Senate in January 2011 after a 30-year career in the U.S. Congress.

On January 25, 2011, Codexis signed its first Japanese biocatalysis collaboration with Dainippon Sumitomo Pharma, one of the ten largest Japanese pharmaceutical manufacturers. Under the agreement, Codexis will supply biocatalysis screening products and services to DSP for use in selected undisclosed therapeutic products in its development pipeline.

On January 12, 2011, Codexis signed an enzyme supply agreement with DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV.  The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn™ route scouting services.

Conference CallCodexis will hold a conference call for investors on May 5, 2011 at 1:30 p.m. PT (4:30 p.m. ET). The conference call dial-in numbers are US: 866-730-5771 or International: 857-350-1595, access code 43195209. A live webcast of the call will also be available from the Investor Relations section of A recording of the call will be available by calling US: 888-286-8010 or International: 617-801-6888, access code 62515565 beginning approximately two hours after the call, and will be available for up to thirty days. A webcast replay from today's call will also be available from the Investor Relations section of approximately two hours after the call and will be available for up to thirty days.

About Codexis, Inc.Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. 

Forward-Looking StatementsThis press release contains forward-looking statements relating to the company's forecast for 2011 revenue and Adjusted EBITDA, which is defined elsewhere in this press release.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 10, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Codexis, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In Thousands, Except Per Share Amounts)Three Months EndedMarch 31,20112010% changeRevenues:Product$
,275106%Related party collaborative research and development14,82316,042-8%Collaborative research and development2,663661303%Government grants6162,722-77%Total revenues 31,03425,70021%Costs and operating expenses: Cost of product revenues11,6505,218123%Gross margin $1,2821,057Gross margin %10%17%Research and development13,75012,9826%Selling, general and administrative9,0138,6005%Total costs and operating expenses34,41326,80028%Loss from operations (3,379)(1,100)207%Interest income492875%Interest expense and other, net17(358)nmLoss before provision (benefit) for income taxes (3,313)(1,430)132%Provision (benefit) for income taxes 158(61)nmNet loss$
(1,369)154%Net loss per share of common stock,basic and diluted$
(0.50)Weighted average common shares used in computing net loss per share of common stock, basic and diluted35,1162,714Codexis, Inc.Condensed Consolidated Balance Sheets(Unaudited)(In Thousands)March 31,December 31,20112010AssetsCurrent assets:   Cash and cash equivalents $
72,396   Marketable securities12,540-   Accounts receivable, net 11,32210,620   Related party accounts receivable-4,713   Inventories 3,2242,817   Prepaid expenses and other current assets2,6171,646Total current assets 82,85592,192Restricted cash1,5121,466Long-term marketable securities16,2961,650Property and equipment, net 20,23921,452Intangible assets, net 19,23020,158Goodwill3,2413,241Other non-current assets 1,1751,141  Total assets $
41,300Liabilities and shareholders' equityCurrent liabilities:   Accounts payable $
9,208   Accrued compensation3,7848,107   Other accrued liabilities 7,4505,630   Deferred revenues 770455   Related party deferred revenues8,6914,084Total current liabilities 30,94027,484Deferred revenues, net of current portion1,6251,671Related party deferred revenues, net of current portion2,3823,403Other long-term liabilities 1,5951,381Total  liabilities 36,54233,939Stockholders' equity:Common stock44Additional paid-in capital279,574275,540Accumulated other comprehensive loss49(34)Accumulated deficit(171,621)(168,149)Total  stockholders' equity108,006107,361  Total liabilities, and shareholders' equity$
41,300Codexis, Inc.Condensed Consolidated Statements of Cash Flow(Unaudited)(In Thousands)Three Months EndedMarch 31,20112010Operating activities:Net loss$
(1,369)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of intangible assets941187Depreciation and amortization of property and equipment1,8951,651Revaluation of redeemable convertible preferred stock warrant liability-396Gain from extinguishment of asset retirement obligation(124)-Stock-based compensation2,3071,655Accretion of asset retirement obligation1736Amortization of debt discount-24Accretion (amortization) of premium/discount on marketable securities(3)(119)Changes in operating assets and liabilities:Accounts receivable4,011685Inventories(407)3Prepaid expenses and other current assets(971)(261)Other assets(48)(71)Accounts payable1,037(2,720)Accrued compensation(4,324)(2,958)Related party payable-(766)Other accrued liabilities2,570(1,372)Deferred revenues3,856(7,026)Net cash provided by (used in) operating activities7,286(12,025)Investing activities:(Increase) decrease  in restricted cash(46)-Purchase of property and equipment(891)(1,320)Purchase of marketable securities(27,104)-Proceeds from maturities of marketable securities-13,610Net cash provided by (used in) investing activities(28,041)12,290Financing activities:Principal payments on financing obligations-(1,339)Payments in preparation for initial public offering-(1,636)Proceeds from exercises of stock options1,485140Net cash provided by (used in) financing activities1,485(2,835)Effect of exchange rate changes on cash and cash equivalents26(18)Net increase in cash and cash equivalents(19,244)(2,588)Cash and cash equivalents:   Beginning of the period72,39631,785   End of the period53,15229,197   Marketable securities at the end of period28,83610,067Cash, cash equivalents and marketable securities$
39,264Reconciliation of GAAP to Non-GAAP Financial InformationIn this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA to evaluate the effectiveness of our business strategies.  

A reconciliation of GAAP net loss to Adjusted EBITDA is included in the table below.

Codexis, Inc.Reconciliation of GAAP Net Loss to Adjusted EBITDA(Unaudited)(In Thousands)Three Months EndedMarch 31,Calculation of Adjusted EBITDA20112010Net loss

(3,471)$   (1,369)Adjustments:Minus: Interest income

(49)(28)Plus: Interest expense

-298Plus: Income taxes

158(61)Plus: Depreciation and amortization

2,8361,838Plus: Stock-based compensation

2,2861,713Plus: Preferred stock warrant fair market valuation adjustment

-396   Adjusted EBITDA$
2,787Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:

  • Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
  • Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
  • Non-cash compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.

  • Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.

    Contacts:  Investors:   Henk Adriaenssens,, 650-421-8331
    Media: Lyn Christenson,, 650-421-8144 or Saskia Sidenfaden,, 212-827-3771.


    SOURCE Codexis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Former Senator Byron Dorgan Elected to Codexis Board
    2. Codexis Reports Fourth Quarter and Full Year 2010 Results
    3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
    4. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
    5. Codexis R&D Productivity Panels Also Used By Roche
    6. Codexis Names Lori Giver VP Systems Biology
    7. Codexis, Teva in Licensing Agreement Final
    8. Codexis Names Vice President, Intellectual Property
    9. Codexis, Arch Announce Expanded Collaboration
    10. Vanda Pharmaceuticals Reports First Quarter 2011 Results
    11. Reportlinker Adds Genetics Reports Bundle
    Post Your Comments:
    (Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
    (Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
    (Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
    (Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
    Breaking Biology Technology:
    (Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
    (Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
    (Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
    Breaking Biology News(10 mins):